Radioembolisation primärer und sekundärer Lebermalignome mit Holmium-166-Mikrosphären – eine kurze Übersicht

 

 Buy Article Permissions and Reprints

Zusammenfassung

Im Rahmen der transarterielle Radioembolisation (TARE) werden überwiegend ⁹⁰Y-markierten Glas- und Harzmikrosphären verwendet. Seit Kurzem sind mit ¹⁶⁶Ho neue Mikrosphären auf Basis von Poly-L-Milchsäure verfügbar, welche auch in Deutschland zunehmend in der klinischen Routine eingesetzt werden. Aufgrund physikalischer Unterschiede bieten ¹⁶⁶Ho-Mikrosphären dabei spezielle Vorteile im Vergleich zur TARE mit ⁹⁰Y-markierten Mikrosphären. In diesem Artikel soll ein kurzer Überblick über die TARE mit ¹⁶⁶Ho-Mikrosphären gegeben werden.

Abstract

Transarterial radioembolization (TARE) predominantly uses ⁹⁰Y-labeled glass and resin microspheres. Recently, new microspheres based on poly-L-lactic acid, ¹⁶⁶Ho, have become available and are increasingly used in clinical routine also in Germany. Due to physical differences, ¹⁶⁶Ho microspheres offer specific advantages compared ⁹⁰Y-labeled microspheres. In this article, a short overview of TARE with 166Ho microspheres will be given.

Publication History

Article published online:
07 December 2023

© 2023. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

• Literatur

• 1 Ahmadzadehfar H, Ilhan H, Lam M. et al. Radioembolization, Principles and indications. Nuklearmedizin 2022; 61: 262-272 DOI: 10.1055/a-1759-4238. (PMID: 35354218)
  Article in Thieme ConnectPubMedGoogle Scholar
• 2 Bierman HR, Byron Jr RL, Kelley KH. et al. Studies on the blood supply of tumors in man. III. Vascular patterns of the liver by hepatic arteriography in vivo. J Natl Cancer Inst 1951; 12: 107-131 (PMID: 14874125)
  PubMedGoogle Scholar
• 3 Mertens A, Essing T, Minko P. et al. Selective internal radiotherapy in Germany: a review of indications and hospital mortality from 2012 to 2019. J Clin Transl Res 2023; 9: 123-132
  PubMedGoogle Scholar
• 4 Smits ML, Nijsen JF, Bosch MA van den. et al. Holmium-166 radioembolization for the treatment of patients with liver metastases: design of the phase I HEPAR trial. J Exp Clin Cancer Res 2010; 29: 70 DOI: 10.1186/1756-9966-29-70.
  CrossrefPubMedGoogle Scholar
• 5 Smits ML, Nijsen JF, Bosch MA van den. et al. Holmium-166 radioembolisation in patients with unresectable, chemorefractory liver metastases (HEPAR trial): a phase 1, dose-escalation study. Lancet Oncol 2012; 13: 1025-1034 DOI: 10.1016/S1470-2045(12)70334-0.
  CrossrefPubMedGoogle Scholar
• 6 Reinders MTM, Erpecum KJ van, Smits MLJ. et al. Safety and Efficacy of (166)Ho Radioembolization in Hepatocellular Carcinoma: The HEPAR Primary Study. J Nucl Med 2022; 63: 1891-1898 DOI: 10.2967/jnumed.122.263823. (PMID: 35589409)
  CrossrefPubMedGoogle Scholar
• 7 Stella M, Braat A, Rooij R van. et al. Holmium-166 Radioembolization: Current Status and Future Prospective. Cardiovasc Intervent Radiol 2022; 45: 1634-1645 DOI: 10.1007/s00270-022-03187-y. (PMID: 35729423)
  CrossrefPubMedGoogle Scholar
• 8 Weber M, Lam M, Chiesa C. et al. EANM procedure guideline for the treatment of liver cancer and liver metastases with intra-arterial radioactive compounds. Eur J Nucl Med Mol Imaging 2022; 49: 1682-1699 DOI: 10.1007/s00259-021-05600-z.
  CrossrefPubMedGoogle Scholar
• 9 Bobin C, Bouchard J, Chiste V. et al. Activity measurements and determination of nuclear decay data of (166)Ho in the MRTDosimetry project. Appl Radiat Isot 2019; 153: 108826 DOI: 10.1016/j.apradiso.2019.108826. (PMID: 31525708)
  CrossrefPubMedGoogle Scholar
• 10 Smits ML, Elschot M, Bosch MA van den. et al. In vivo dosimetry based on SPECT and MR imaging of 166Ho-microspheres for treatment of liver malignancies. J Nucl Med 2013; 54: 2093-2100 DOI: 10.2967/jnumed.113.119768. (PMID: 24136931)
  CrossrefPubMedGoogle Scholar
• 11 Reinders MTM, Smits MLJ, Roekel C van. et al. Holmium-166 Microsphere Radioembolization of Hepatic Malignancies. Semin Nucl Med 2019; 49: 237-243 DOI: 10.1053/j.semnuclmed.2019.01.008. (PMID: 30954190)
  CrossrefPubMedGoogle Scholar
• 12 Ilhan H, Goritschan A, Paprottka P. et al. Predictive Value of 99mTc-MAA SPECT for 90Y-Labeled Resin Microsphere Distribution in Radioembolization of Primary and Secondary Hepatic Tumors. J Nucl Med 2015; 56: 1654-1660 DOI: 10.2967/jnumed.115.162685. (PMID: 26315830)
  CrossrefPubMedGoogle Scholar
• 13 Smits MLJ, Dassen MG, Prince JF. et al. The superior predictive value of (166)Ho-scout compared with (99m)Tc-macroaggregated albumin prior to (166)Ho-microspheres radioembolization in patients with liver metastases. Eur J Nucl Med Mol Imaging 2020; 47: 798-806 DOI: 10.1007/s00259-019-04460-y.
  CrossrefPubMedGoogle Scholar
• 14 Maat GH van de, de Leeuw H, Seevinck PR. et al. Simultaneous R2*, R2, and R2' quantification by combining S0 estimation of the free induction decay with a single spin echo: A single acquisition method for R2 insensitive quantification of holmium-166-loaded microspheres. Magn Reson Med 2015; 73: 273-283 DOI: 10.1002/mrm.25138.
  CrossrefPubMedGoogle Scholar
• 15 Nijsen JF, Seppenwoolde JH, Havenith T. et al. Liver tumors: MR imaging of radioactive holmium microspheres – phantom and rabbit study. Radiology 2004; 231: 491-499 DOI: 10.1148/radiol.2312030594. (PMID: 15031432)
  CrossrefPubMedGoogle Scholar
• 16 Maat GH van de, Seevinck PR, Elschot M. et al. MRI-based biodistribution assessment of holmium-166 poly(L-lactic acid) microspheres after radioembolisation. Eur Radiol 2013; 23: 827-835 DOI: 10.1007/s00330-012-2648-2. (PMID: 23014797)
  CrossrefPubMedGoogle Scholar
• 17 Roosen J, Wijk MWM van, Westlund Gotby LEL. et al. Improving MRI-based dosimetry for holmium-166 transarterial radioembolization using a nonrigid image registration for voxelwise DeltaR2 * calculation. Med Phys 2023; 50: 935-946 DOI: 10.1002/mp.16014.
  CrossrefPubMedGoogle Scholar
• 18 Braat A, Prince JF, Rooij R van. et al. Safety analysis of holmium-166 microsphere scout dose imaging during radioembolisation work-up: A cohort study. Eur Radiol 2018; 28: 920-928 DOI: 10.1007/s00330-017-4998-2. (PMID: 28786008)
  CrossrefPubMedGoogle Scholar
• 19 Quirem. QuiremSpheres Microspheres Fachinformation. 2022
  PubMedGoogle Scholar
• 20 Roekel C van, Harlianto NI, Braat A. et al. Evaluation of the Safety and Feasibility of Same-Day Holmium-166 -Radioembolization Simulation and Treatment of Hepatic Metastases. J Vasc Interv Radiol 2020; 31: 1593-1599 DOI: 10.1016/j.jvir.2020.01.032. (PMID: 32861571)
  CrossrefPubMedGoogle Scholar
• 21 Andel D, Lam M, Bruijne J de. et al. Dose finding study for unilobar radioembolization using holmium-166 microspheres to improve resectability in patients with HCC: the RALLY protocol. BMC Cancer 2023; 23: 771 DOI: 10.1186/s12885-023-11280-9.
  CrossrefPubMedGoogle Scholar
• 22 Bastiaannet R, Roekel C van, Smits MLJ. et al. First Evidence for a Dose-Response Relationship in Patients Treated with (166)Ho Radioembolization: A Prospective Study. J Nucl Med 2020; 61: 608-612 DOI: 10.2967/jnumed.119.232751.
  CrossrefPubMedGoogle Scholar
• 23 Roekel C van, Bastiaannet R, Smits MLJ. et al. Dose-Effect Relationships of (166)Ho Radioembolization in Colorectal Cancer. J Nucl Med 2021; 62: 272-279 DOI: 10.2967/jnumed.120.243832. (PMID: 32591491)
  CrossrefPubMedGoogle Scholar
• 24 Prince JF, Bosch M van den, Nijsen JFW. et al. Efficacy of Radioembolization with (166)Ho-Microspheres in Salvage Patients with Liver Metastases: A Phase 2 Study. J Nucl Med 2018; 59: 582-588 DOI: 10.2967/jnumed.117.197194.
  CrossrefPubMedGoogle Scholar
• 25 Braat A, Bruijnen RCG, Rooij R van. et al. Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 study. Lancet Oncol 2020; 21: 561-570 DOI: 10.1016/S1470-2045(20)30027-9.
  CrossrefPubMedGoogle Scholar
• 26 Drescher R, Kohler A, Seifert P. et al. Clinical Results of Transarterial Radioembolization (TARE) with Holmium-166 Microspheres in the Multidisciplinary Oncologic Treatment of Patients with Primary and Secondary Liver Cancer. Biomedicines 2023; 11 DOI: 10.3390/biomedicines11071831.
  CrossrefPubMedGoogle Scholar
• 27 Beyer L, Gosewisch A, Lindner S. et al. Dosimetry and optimal scan time of [(18)F]SiTATE-PET/CT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2021; 48: 3571-3581 DOI: 10.1007/s00259-021-05351-x.
  CrossrefPubMedGoogle Scholar